BIOFRONTERA INC (BFRI) Stock Price & Overview
NASDAQ:BFRI • US09077D2099
Current stock price
The current stock price of BFRI is 0.811 USD. Today BFRI is down by -4.4%. In the past month the price decreased by -4.54%. In the past year, price decreased by -0.25%.
BFRI Key Statistics
- Market Cap
- 9.448M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.18
- Dividend Yield
- N/A
BFRI Stock Performance
BFRI Stock Chart
BFRI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BFRI. When comparing the yearly performance of all stocks, BFRI turns out to be only a medium performer in the overall market: it outperformed 62.68% of all stocks.
BFRI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BFRI. Both the profitability and financial health of BFRI have multiple concerns.
BFRI Earnings
On March 19, 2026 BFRI reported an EPS of 0.48 and a revenue of 17.10M. The company beat EPS expectations (142.84% surprise) and beat revenue expectations (3.83% surprise).
BFRI Forecast & Estimates
8 analysts have analysed BFRI and the average price target is 6.12 USD. This implies a price increase of 654.62% is expected in the next year compared to the current price of 0.811.
For the next year, analysts expect an EPS growth of 92.63% and a revenue growth 12.05% for BFRI
BFRI Groups
Sector & Classification
BFRI Financial Highlights
Over the last trailing twelve months BFRI reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 71.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.99% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BFRI Ownership
BFRI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.83 | 851.873B | ||
| JNJ | JOHNSON & JOHNSON | 20.2 | 566.674B | ||
| MRK | MERCK & CO. INC. | 22.49 | 287.712B | ||
| PFE | PFIZER INC | 9.03 | 153.358B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.06 | 116.873B | ||
| ZTS | ZOETIS INC | 16.38 | 48.938B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.82 | 26.288B | ||
| VTRS | VIATRIS INC | 5.33 | 15.383B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.67 | 12.38B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.12B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.658B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.31B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.75 | 4.021B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BFRI
Company Profile
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Company Info
IPO: 2021-10-14
BIOFRONTERA INC
120 Presidential Way,, Suite 330
Woburn MASSACHUSETTS US
CEO: Erica Monaco
Employees: 92
Phone: 18004831140
BIOFRONTERA INC / BFRI FAQ
What does BFRI do?
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
What is the current price of BFRI stock?
The current stock price of BFRI is 0.811 USD. The price decreased by -4.4% in the last trading session.
Does BFRI stock pay dividends?
BFRI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BFRI stock?
BFRI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for BFRI stock?
8 analysts have analysed BFRI and the average price target is 6.12 USD. This implies a price increase of 654.62% is expected in the next year compared to the current price of 0.811.
How is the valuation of BIOFRONTERA INC (BFRI) based on its PE ratio?
BIOFRONTERA INC (BFRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).